On Wednesday, Enveric Biosciences Inc. (NASDAQ:ENVB), a biotechnology firm developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological conditions, released results from a quantitative electroencephalography study assessing its lead compound, EB-003.…
Read More
Enveric Biosciences (NASDAQ: ENVB) has reported new preclinical findings for EB-003, an experimental drug being developed to deliver potential neurological benefits associated with psychedelics without producing hallucinogenic effects. Announced on…
Read More
For a drug designed to change how the brain functions, reaching the brain is only part of the story. Understanding what happens once it gets there can help shape the…
Read More
With an addition to its website — a psychedelic resource page — it seems the FDA is increasingly interested in psychedelic drug development. But even with the growing regulatory interest,…
Read More
The Psychedelic Drugs resource page added to the FDA website might be yet another indicator that the regulator is increasingly interested in the field’s potential. In publishing this resource page,…
Read More
Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003. The company aims to treat psychiatric and neurological disorders by preserving…
Read More
In this Q&A, Tucker explains what set Enveric apart from the first wave of psychedelic biotech companies: rather than rushing traditional molecules into the clinic, the team chose to do…
Read More
As clinical research advances beyond first-generation compounds, scientists are rethinking what psychedelic-inspired therapies could look like and how they may reshape the future of mental healthcare. Full Article >>
Read More
OpenAI CEO Sam Altman, once a “very anxious, unhappy person,” credits a psychedelic experience at a weekend-long retreat with helping him become a new man. He’s not unique among Silicon…
Read More
U.S. President Donald Trump's executive order to accelerate psychedelic drug development has raised hopes among companies developing the drugs that it could help attract more capital, but researchers cautioned that…
Read More

